Trial Profile
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Registrational; Therapeutic Use
- Acronyms EXPLORER-HCM
- Sponsors MyoKardia
- 14 Nov 2023 Results of prespecified post hoc analysis from explorer HCM trial assessing baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men published in the Circulation
- 13 Nov 2023 Results of exploratory subgroup analysis (n=190) assessing the effect of HCM-specific sarcomere gene variants on response to mavacamten presented at the American Heart Association Scientific Sessions 2023
- 13 Nov 2023 Results assessing the effect of 30 weeks of mavacamten treatment versus placebo on levels of intravascular hemolysis biomarkers in patients with obstructive HCM presented at the American Heart Association Scientific Sessions 2023